SCHEMBL20119986

SCHEMBL20119986

Clc1nc(NCc2ccnnc2)c2cc[nH]c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.42
PDE5A O76074 1/20 0.42
PDE2A O00408 4/20 0.38
TTBK1 Q5TCY1 1/20 0.34
TTBK2 Q6IQ55 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
TMIGD3 P0DMS9 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
CLK4 Q9HAZ1 2/20 0.33
CLK2 P49760 1/20 0.33
AURKB Q96GD4 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29833956 0.85 PDE5A (0.48) APPPDE5APDE2ATTBK1TTBK2
SCHEMBL20119397 0.85 PDE5A (0.48) APPPDE5APDE2ATTBK1TTBK2
SCHEMBL20119919 0.83 PKM (0.50) APPPDE5ACLK4USP2ALDH1A1
SCHEMBL20119894 0.79 CYP1A2 (0.42) APPPDE5APDE2ATMIGD3HTR2C
SCHEMBL20119756 0.79 KCNH3 (0.44) APPPDE5APDE2ATTBK1TTBK2
SCHEMBL20119384 0.78 TMIGD3 (0.41) APPPDE5APDE2ATMIGD3HTR2C
SCHEMBL20119845 0.77 APP (0.44) APPPDE5ATTBK1TTBK2TMIGD3
SCHEMBL20119452 0.76 PDE5A (0.42) APPPDE5APDE2ATTBK1TTBK2
SCHEMBL20119988 0.76 LOX (0.41) APPPDE5APDE2ATMIGD3HTR2C
SCHEMBL20119599 0.75 PDE2A (0.41) APPPDE5APDE2ACLK4CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885PDE2A 2550/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885PDE2A 2550/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885PDE2A 2550/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885PDE2A 2550/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 APP 604/4885PDE5A 3202/4885PDE2A 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.